A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer
Latest Information Update: 26 Dec 2023
At a glance
- Drugs MB 1707 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mainline Biosciences
Most Recent Events
- 16 Dec 2023 Status changed from not yet recruiting to withdrawn prior to enrolment as per sponsor decision.
- 27 Jul 2022 New trial record